Clinical Study of CAR-T Technique in the Treatment of Recurrent and Refractory Hematopoietic and Lymphatic Tumor
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Safety: Incidence and severity of adverse events
研究概览
简要总结
To evaluate the safety of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors
详细描述
Main research objective: To evaluate the safety of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors. Secondary research objective: To investigate the efficacy and cytodynamic characteristics of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 14 Years 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •With the consent of himself or the legal guardian and the signed informed consent, he is willing and able to comply with the planned visit, research and treatment, laboratory examination and other test procedures; Clinical Study of CAR-T Technique in the Treatment of Recurrent and Refractory Hematopoietic and Lymphatic Tumor
- •Patients with recurrent and refractory hematopoiesis and lymphoid tissue tumors determined by clinical diagnosis;
- •Age 14-70 (including boundary value), both male and female;
- •Subjects with a physical status of 0~2 in the American Eastern Oncology Collaboration Group (ECOG);
- •The results of treatment related antigens were positive;
- •The expected life span is more than 3 months from the date of signing the informed consent;
排除标准
- 未提供
结局指标
主要结局
Safety: Incidence and severity of adverse events
时间窗: 24 months post CAR-T cells infusion
The incidence and severity of adverse events and adverse reactions from infusion to withdrawal or before the safety follow-up period
次要结局
未报告次要终点